--- title: "EU Drug Report 2026: Cannabis remains… | Cannabivo" description: "The EU Drug Report 2026 says cannabis remains Europe’s most used illicit drug, while courts, ministries and pilot schemes expose a fragmented policy landscape." canonical: https://cannabivo.com/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen language: en robots: index, follow og_type: article type: research-article language_alternates: en: https://cannabivo.com/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen.md cs: https://cannabivo.com/cs/novinky/veda/evropska-zprava-o-drogach-2026-konopi-zustava-nejpouzivanejsi-nelegalni-droga-v-evrope-rozpory-v-politice.md de: https://cannabivo.com/de/news/wissenschaft/eu-drogenbericht-2026-cannabis-bleibt-europas-meistgenutzte-illegale-droge-waehrend-politische-risse-wachsen.md es: https://cannabivo.com/es/noticias/ciencia/informe-de-drogas-de-la-ue-2026-el-cannabis-sigue-siendo-la-droga-ilicita-mas-consumida-en-europa-mientras-se-amplian-las-fracturas-politicas.md fr: https://cannabivo.com/fr/actualites/science/rapport-europeen-sur-les-drogues-2026-le-cannabis-reste-la-drogue-illicite-la-plus-consommee-en-europe-tandis-que-les-fractures-politiques-se-largissent.md hu: https://cannabivo.com/hu/hirek/tudomany/eu-drogjelentes-2026-a-kannabisz-tovabbra-is-europa-leggyakrabban-hasznalt-illegalis-drogja-mikozben-a-politikai-toresvonalak-szelesednek.md it: https://cannabivo.com/it/notizie/scienza/rapporto-ue-sulle-droghe-2026-la-cannabis-resta-la-droga-illecita-piu-diffusa-in-europa-mentre-si-allargano-le-fratture-politiche.md nl: https://cannabivo.com/nl/nieuws/wetenschap/eu-drugrapport-2026-cannabis-blijft-europas-meest-gebruikte-illegale-drug-terwijl-beleidsversplintering-toeneemt.md pl: https://cannabivo.com/pl/aktualnosci/nauka/raport-ue-o-narkotykach-2026-konopie-pozostaja-najczesciej-uzywanym-nielegalnym-narkotykiem-w-europie-podzialy.md pt: https://cannabivo.com/pt/noticias/ciencia/relatorio-da-ue-sobre-drogas-2026-cannabis-mantem-se-como-droga-ilicita-mais-usada-na-europa-enquanto-fraturas-politicas-se-alargam.md ru: https://cannabivo.com/ru/novosti/nauka/evropeyskiy-doklad-po-narkotikam-2026-kannabis-ostaetsya-samym-upotreblyaemym-nelegalnym-narkotikom-raznoglasiya-rasshirayutsya.md tr: https://cannabivo.com/tr/haberler/bilim/ab-uyusturucu-raporu-2026-kenevir-politika-ayrismlari-derinlesirken-avrupanin-en-cok-kullanilan-yasa-disi-uyusturucusu.md zh: https://cannabivo.com/zh/news/kexue/2026-nian-oumeng-dupin-baogao-dama-reng-wei-ouzhou-shiyong-zui-guang-de-feifa-yaowu-zhengce-fenji-jiaju.md ja: https://cannabivo.com/ja/news/kagaku/eu-yakubutsu-hokokusho-2026-seisaku-no-bunretsu-ga-hirogaru-naka-cannabis-wa-izen-to-shite-oushu-de-mottomo-shiyou-sareru-ihou-yakubutsu.md ar: https://cannabivo.com/ar/akhbar/ilm/taqrir-al-mukhadirat-fi-al-ittihad-al-oorobi-2026-al-qannab-yabqa-akthar-al-mukhadirat-ghair-al-mashrua-istikhdaman-fi-oroba-bayna-tawassa-shuqooq-al-siyasah.md ko: https://cannabivo.com/ko/news/gwahak/eu-yagmul-bogoseo-2026-daemacho-neun-yureop-eseo-gajang-mani-sayongdoeneun-beolbeop-yakmul-jeongchaek-bunyeol-simhwa.md pt-br: https://cannabivo.com/pt-br/noticias/ciencia/relatorio-da-ue-sobre-drogas-2026-a-cannabis-continua-sendo-a-droga-ilicita-mais-usada-na-europa-enquanto-as-fissuras-politicas-se-ampliam.md hi: https://cannabivo.com/hi/samachar/vigyan/eu-drug-report-2026-kainabis-yurop-ki-sabse-adhik-istamal-hone-wali-avaidh-dawa.md generated: 2026-07-31 --- > **Machine-readable Markdown rendering.** This is a Markdown representation of a web page, > served for AI agents and crawlers as a token-efficient alternative to the full HTML. > Full interactive HTML version: https://cannabivo.com/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen > Canonical URL: https://cannabivo.com/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen > Available languages: en, cs, de, es, fr, hu, it, nl, pl, pt, ru, tr, zh, ja, ar, ko, pt-br, hi [![Abstract editorial scene of European institutions, reports and legal documents on cannabis policy](/images/uploads/a7232efd-cbf5-4227-bf76-8aaec0f923e8/news-hero-eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-f-1920x1080.jpg)](/images/uploads/a7232efd-cbf5-4227-bf76-8aaec0f923e8/news-hero-eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-f-1920x1080.avif "View image full size") [Science](/news/science "Science") 9 min read # EU Drug Report 2026: Cannabis remains Europe’s most used illicit drug as policy fractures widen ![Portrait of Rob Harley, Cannabivo news desk](/images/uploads/5f094d99-3443-4907-8555-2910851fd38a/rob-harley-1920x1920.jpg)By [Rob Harley](/user-profile?u=a65dddce-73db-40b5-8660-fe93612a7384 "View the author's member profile")Published June 13, 2026in [Science](/news/science "Science") The EU Drug Report 2026 says cannabis remains Europe’s most used illicit drug, while courts, ministries and pilot schemes expose a fragmented policy landscape. ![Portrait of Rob Harley, Cannabivo news desk](/images/uploads/5f094d99-3443-4907-8555-2910851fd38a/rob-harley-1920x1920.jpg)By [Rob Harley](/user-profile?u=a65dddce-73db-40b5-8660-fe93612a7384 "View the author's member profile") Rob Harley has reported on cannabis law and the non-profit association movement across Europe for the past decade. He focuses on how regulation actually reaches the members who use cannabis social clubs — the paperwork, the limits, and the slow build of public trust. His work for Cannabivo aims to be accurate, sourced, and free of hype. [More articles by this author](/news/author/rob-harley "See all articles by this author")Published June 13, 2026in [Science](/news/science "Science") In this article1. [Cannabis still dominates Europe’s illicit-drug picture](/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen#cannabis-still-dominates-europe-s-illicit-drug-picture "Cannabis still dominates Europe’s illicit-drug picture") 2. [A fragmented legal map keeps shaping access and enforcement](/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen#a-fragmented-legal-map-keeps-shaping-access-and-enforcement "A fragmented legal map keeps shaping access and enforcement") 3. [Germany, France and Hungary show how uneven the debate has become](/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen#germany-france-and-hungary-show-how-uneven-the-debate-has-become "Germany, France and Hungary show how uneven the debate has become") 4. [Medical cannabis is expanding, but not in a straight line](/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen#medical-cannabis-is-expanding-but-not-in-a-straight-line "Medical cannabis is expanding, but not in a straight line") 5. [Stricter rules are arriving around the edges](/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen#stricter-rules-are-arriving-around-the-edges "Stricter rules are arriving around the edges") 6. [What the new report adds to Europe’s policy argument](/news/science/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-widen#what-the-new-report-adds-to-europe-s-policy-argument "What the new report adds to Europe’s policy argument") Cannabis sits at the center of Europe’s latest drug-policy picture, but not in a settled way. The EU Drug Report 2026 says it remains the continent’s most commonly used illicit drug, even as national rules, court rulings, pilot schemes and tightening enforcement continue to pull policy in different directions. That tension runs through the new report, which arrives alongside fresh disputes over medical access, supply controls and the legal boundaries of cannabis regulation in Europe. ## Cannabis still dominates Europe’s illicit-drug picture The European Union’s latest assessment puts **cannabis** at the center of the continent’s drug landscape. In the [EUDA’s cannabis chapter for the 2026 European Drug Report](https://www.euda.europa.eu/publications/european-drug-report/2026/cannabis_en "EUDA’s cannabis chapter for the 2026 European Drug Report"), the agency says cannabis remains the most commonly used illicit drug in Europe. A separate summary of the report says around **25 million** Europeans used cannabis, underlining how large the market remains even as the policy debate grows more complicated. The report’s headline numbers 25 millionestimated cannabis users in Europe 24.9 millionadults reporting use in the past year 68%share of drug seizures accounted for by cannabis in 2024 8.4%European adults reporting use The report does not describe a static market. Other coverage of the same EUDA release notes that Europe’s drug market is becoming more complex, with new synthetic products gaining ground even as cannabis stays the most familiar illicit substance. That combination matters: cannabis is still the scale leader, but it is now being measured inside a broader landscape of shifting enforcement priorities and changing product risks. [![Abstract editorial scene of a European briefing room with maps, report pages and regulatory motifs.](/images/uploads/3050e819-d7b4-4f40-86e6-526e047e9bc6/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-w-1920x1080.jpg)](/images/uploads/3050e819-d7b4-4f40-86e6-526e047e9bc6/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-w-1920x1080.avif "View image full size") The EU Drug Report 2026 places cannabis at the center of a more complex European drug market. ## A fragmented legal map keeps shaping access and enforcement The report’s significance is not just in the usage figures. It also lands in a Europe where there is still no harmonised EU law on illicit cannabis, a point the EUDA has made in its [FAQ on cannabis laws in Europe](https://www.euda.europa.eu/publications/faqs/cannabis-laws-in-europe-faq/how-do-eu-countries-respond-illegal-use-and-supply-cannabis_en "FAQ on cannabis laws in Europe"). EU law can set minimum rules for serious cross-border drug trafficking, but day-to-day rules on possession, supply, medical access and cultivation remain national territory. How the European cannabis landscape is splitting by policy area | Policy area | What the supplied facts show | Source | |---|---|---| | Illicit-use rules | No harmonised EU law; member states keep their own approaches | [EUDA cannabis laws FAQ](https://www.euda.europa.eu/publications/faqs/cannabis-laws-in-europe-faq/how-do-eu-countries-respond-illegal-use-and-supply-cannabis_en "EUDA cannabis laws FAQ") | | Medical access | National systems vary widely on prescribing, access and reimbursement | [Medical Cannabis in Europe: Which Countries Allow It?](https://cannabis-europa.com/insights/medical-cannabis-europe/ "Medical Cannabis in Europe: Which Countries Allow It?") | | Cross-border supply | Minimum EU rules can apply to serious trafficking, but not a single adult-use framework | [EUDA cannabis laws FAQ](https://www.euda.europa.eu/publications/faqs/cannabis-laws-in-europe-faq/how-do-eu-countries-respond-illegal-use-and-supply-cannabis_en "EUDA cannabis laws FAQ") | | Regulatory pressure on products | EU countries are introducing stricter treatment of hemp and cannabis-derived foods and flower products | [EURACTIV report on tighter treatment of hemp and cannabis products](https://euractiv.com/de/news/cannabis-lebensmittel-und-blueten-werden-in-europa-zunehmend-streng-behandelt/ "EURACTIV report on tighter treatment of hemp and cannabis products") | ## Germany, France and Hungary show how uneven the debate has become Three recent European developments capture the range of the current debate. In Germany, cannabis reform remains politically contested, with [The Guardian reporting that the health minister called the relaxed policy a mistake](https://www.theguardian.com/society/2026/apr/01/report-germany-cannabis-legalisation-fails-settle-debate "The Guardian reporting that the health minister called the relaxed policy a mistake") and an interim report finding cannabis clubs still play only a minor role. In France, medical access is still in motion: one report says the pilot has been extended to **2027**, while other coverage says officials have outlined reimbursement plans but the legislation needed for a lasting framework remains blocked. Hungary adds a different layer entirely. In January, the Court of Justice of the European Union ruled that Hungary breached EU law by voting against the EU’s common position on cannabis rescheduling at the UN. The case matters beyond the immediate dispute because it shows how cannabis policy can trigger not just domestic argument but also questions about whether member states can break ranks on EU positions in international forums. [![Cartographic illustration of Europe with highlighted member states, legal papers and public buildings.](/images/uploads/57544f31-fe72-45fd-b241-7ad87a1376c8/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-w-1920x1080.jpg)](/images/uploads/57544f31-fe72-45fd-b241-7ad87a1376c8/eu-drug-report-2026-cannabis-remains-europe-s-most-used-illicit-drug-as-policy-fractures-w-1920x1080.avif "View image full size") Germany, France and Hungary illustrate the uneven political and legal landscape around cannabis in Europe.- Germany: political arguments continue over the direction and impact of reform. - France: medical cannabis access has been prolonged, but permanent law is still unresolved. - Hungary: the EU’s top court found a breach of EU law in a cannabis-related UN vote. ## Medical cannabis is expanding, but not in a straight line Europe’s medical market is one of the clearest signs that cannabis policy is moving, even when adult-use debates remain stalled. A report on Spain says [Taima Growth became the country’s fourth AEMPS-licensed medical cannabis cultivator](https://businessofcannabis.com/taima-growth-becomes-spains-fourth-aemps-licensed-medical-cannabis-cultivator/ "Taima Growth became the country’s fourth AEMPS-licensed medical cannabis cultivator"), giving the startup a role in a sector that is still tightly regulated and closely tied to export markets. Elsewhere, a separate piece on England argues that a small number of doctors may be responsible for a large share of private medical cannabis prescribing, a reminder that access can remain highly concentrated even where the market appears established. The broader European picture is one of fragmentation rather than convergence. A 2026 Chambers guide says Germany remains Europe’s largest medical cannabis market, while France’s broader access framework has repeatedly been delayed. A Muzo Health overview makes the same point more bluntly: national rules, reimbursement systems and cross-border supply still vary widely across the continent. That is also why commercial attention keeps shifting toward regulatory openings rather than a single European market. Context Medical cannabis in Europe is growing, but the supplied facts describe a patchwork system: different rules on prescribing, reimbursement, cultivation and export, with no single continent-wide model. Selected medical-cannabis developments mentioned in the supplied facts | Country or market | What changed | Source | |---|---|---| | Spain | Taima Growth became the fourth AEMPS-licensed medical cannabis cultivator | [Business of Cannabis on Taima Growth](https://businessofcannabis.com/taima-growth-becomes-spains-fourth-aemps-licensed-medical-cannabis-cultivator/ "Business of Cannabis on Taima Growth") | | France | Pilot extended through 2027; reimbursement plans were outlined but permanent law remains unresolved | [Hanf Magazin on France’s pilot extension](https://www.hanf-magazin.com/en/frankreich-pilotphase-cannabis-verlaengert-bis-2027/ "Hanf Magazin on France’s pilot extension") | | Germany | Still described as Europe’s largest medical cannabis market | [Chambers medical cannabis guide](https://practiceguides.chambers.com/practice-guides/medical-cannabis-psychedelic-medicines-2026 "Chambers medical cannabis guide") | | England | Questions raised over whether a small group of doctors accounts for a large share of prescribing | [Business of Cannabis on prescribing concentration](https://businessofcannabis.com/do-10-doctors-really-prescribe-half-of-englands-medical-cannabis/ "Business of Cannabis on prescribing concentration") | ## Stricter rules are arriving around the edges While the EUDA report focuses on the broad drug picture, other recent coverage points to a tightening environment around cannabis-related products and enforcement. [EURACTIV reported that EU countries are introducing new restrictions on hemp and cannabis-derived foods and flower products](https://euractiv.com/de/news/cannabis-lebensmittel-und-blueten-werden-in-europa-zunehmend-streng-behandelt/ "EURACTIV reported that EU countries are introducing new restrictions on hemp and cannabis-derived foods and flower products"), suggesting that regulators are not only dealing with illicit supply but also with the boundaries of semi-legal or consumer-facing cannabis products. Enforcement pressure is also rising at the political level. EURACTIV said EU leaders are considering tougher action against drug gangs, while MJBizDaily reported that ministers from Germany, Malta, the Netherlands and Luxembourg discussed adult-use cannabis policy hurdles. Those discussions point to a familiar problem: Europe is debating cannabis policy across several overlapping fields at once — policing, health, trade and regulation — without a common adult-use framework to tie them together. > “Status quo not a tenable option” was how ministers framed the policy hurdles, according to MJBizDaily’s report on the meeting. > > MJBizDaily ## What the new report adds to Europe’s policy argument Taken together, the EUDA report and the surrounding 2026 coverage show a continent in transition but not in alignment. Cannabis is still the most widely used illicit drug, yet the policy environment around it is moving in different directions at once. Some governments are tightening product rules; others are extending medical pilots; courts are policing the limits of member-state autonomy; and some political actors are still pushing for broader reform, even while others back away from it. That is why the report matters beyond the annual headline. It does not simply say that cannabis use is widespread. It places that fact inside a Europe where the legal and commercial meaning of cannabis remains unsettled. For readers trying to understand the current situation in Europe, the key point is not just prevalence, but fragmentation: a large market, a moving regulatory target and no single endpoint in sight. What the 2026 European Drug Report means for cannabis - Cannabis remains Europe’s most commonly used illicit drug, with the EUDA linking the topic to about 25 million users. - The legal picture is still fragmented: there is no harmonised EU law on illicit cannabis, and national rules continue to diverge. - Medical cannabis is expanding in some countries, but access, prescribing and reimbursement remain uneven. - Recent court rulings, tighter product rules and political disputes show that cannabis policy in Europe is still unsettled. The 2026 European Drug Report confirms cannabis’s scale in Europe, but the bigger story is the lack of a settled policy model. Across the continent, the facts point to a market that is large, politically contested and regulated through a patchwork of national choices rather than a unified European approach. ## Sources 1. [EU Drug Report 2026: Cannabis – the current situation in Europe (euda.europa.eu)](https://www.euda.europa.eu/publications/european-drug-report/2026/cannabis_en "Open source in a new tab: https://www.euda.europa.eu/publications/european-drug-report/2026/cannabis_en") 2. [EUDA cannabis laws in Europe FAQ: How do EU countries respond to illegal use and supply of cannabis? (euda.europa.eu)](https://www.euda.europa.eu/publications/faqs/cannabis-laws-in-europe-faq/how-do-eu-countries-respond-illegal-use-and-supply-cannabis_en "Open source in a new tab: https://www.euda.europa.eu/publications/faqs/cannabis-laws-in-europe-faq/how-do-eu-countries-respond-illegal-use-and-supply-cannabis_en") 3. [Medical Cannabis in Europe: Which Countries Allow It? (cannabis-europa.com)](https://cannabis-europa.com/insights/medical-cannabis-europe/ "Open source in a new tab: https://cannabis-europa.com/insights/medical-cannabis-europe/") 4. [Cannabis-Lebensmittel und -Blüten werden in Europa zunehmend streng behandelt (euractiv.com)](https://euractiv.com/de/news/cannabis-lebensmittel-und-blueten-werden-in-europa-zunehmend-streng-behandelt/ "Open source in a new tab: https://euractiv.com/de/news/cannabis-lebensmittel-und-blueten-werden-in-europa-zunehmend-streng-behandelt/") 5. [High times or low blows? Experts fail to clear air over German drug legalisation (theguardian.com)](https://www.theguardian.com/society/2026/apr/01/report-germany-cannabis-legalisation-fails-settle-debate "Open source in a new tab: https://www.theguardian.com/society/2026/apr/01/report-germany-cannabis-legalisation-fails-settle-debate") 6. [Taima Growth Becomes Spain’s Fourth AEMPS-Licensed Medical Cannabis Cultivator (businessofcannabis.com)](https://businessofcannabis.com/taima-growth-becomes-spains-fourth-aemps-licensed-medical-cannabis-cultivator/ "Open source in a new tab: https://businessofcannabis.com/taima-growth-becomes-spains-fourth-aemps-licensed-medical-cannabis-cultivator/") 7. [France Cannabis Pilot Extended to 2027 | Medical Access Delayed (hanf-magazin.com)](https://www.hanf-magazin.com/en/frankreich-pilotphase-cannabis-verlaengert-bis-2027/ "Open source in a new tab: https://www.hanf-magazin.com/en/frankreich-pilotphase-cannabis-verlaengert-bis-2027/") 8. [Medical Cannabis & Psychedelic Medicines 2026 (practiceguides.chambers.com)](https://practiceguides.chambers.com/practice-guides/medical-cannabis-psychedelic-medicines-2026 "Open source in a new tab: https://practiceguides.chambers.com/practice-guides/medical-cannabis-psychedelic-medicines-2026") 9. [Do 10 Doctors Really Prescribe Half of England’s Medical Cannabis? (businessofcannabis.com)](https://businessofcannabis.com/do-10-doctors-really-prescribe-half-of-englands-medical-cannabis/ "Open source in a new tab: https://businessofcannabis.com/do-10-doctors-really-prescribe-half-of-englands-medical-cannabis/")